Literature DB >> 20851475

Anticoagulation remains underused in prevention of stroke associated with atrial fibrillation: insights from two consecutive national surveys.

Yvonne Schwammenthal1, Nathan M Bornstein, Uri Goldbourt, Silvia Koton, Roseline Schwartz, Nina Koren-Morag, Ehud Grossman, David Tanne.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is a major risk factor of ischemic stroke. We tested whether the adoption of the CHADS(2) score in clinical guidelines has impacted treatment strategies for stroke prevention, and examined how AF affects stroke outcome.
METHODS: In the setting of two national surveys [National Acute Stroke Israeli Surveys; all patients hospitalized for stroke in Israel during February-March 2004, and March-April 2007] data of patients with and without AF were analyzed with respect to patient characteristics, use of anticoagulation, stroke severity, clinical course, and long-term outcome.
RESULTS: Of 3040 patients with acute ischemic stroke, 586 patients (19%) had a history of AF. Severe strokes on admission were significantly more frequent in patients with AF, as was the proportion of total anterior circulation strokes. Ischemic stroke associated with AF predicted poor outcome at discharge (adjusted OR 1.56; 95%CI 1.24-1.96) and higher mortality rates throughout follow-up. Among patients with a CHADS(2) score ≥ 2 prior to the index stroke and without known contraindications, 41% received anticoagulation. This proportion increased to only 62% after the index stroke, even after excluding patients with severe disability and no significant increase between 2004 and 2007 was detectable. Increasing age, in-hospital infectious complications, and unfavorable functional status at discharge were independently associated with decreased likelihood of receiving anticoagulation.
CONCLUSIONS: In deviation from current recommendations and in spite of the introduction of CHADS(2) criteria, anticoagulation for stroke prevention remains underutilized, despite the particularly poor outcome of strokes associated with AF.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851475     DOI: 10.1016/j.ijcard.2010.08.005

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

1.  Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea.

Authors:  Wook Joo Kim; Jong Moo Park; Kyusik Kang; Yong Jin Cho; Keun Sik Hong; Soo Joo Lee; Youngchai Ko; Kyung Bok Lee; Tai Hwan Park; Jun Lee; Jae Kwan Cha; Dae Hyun Kim; Kyung Ho Yu; Byung Chul Lee; Mi Sun Oh; Juneyoung Lee; Jisung Lee; Myung Suk Jang; Moon Ku Han; Hee Joon Bae
Journal:  J Clin Neurol       Date:  2015-11-04       Impact factor: 3.077

2.  The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: A drug utilization study using claims data in Japan.

Authors:  Kiyoshi Kubota; Nobuhiro Ooba; Yukari Kamijima; Kuniyasu Sato; Daisuke Koide
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.